Specialized in pharmacology journal publishes in its January issue
its updated to avoid drugs because of their side effects list.
They are " drugs away for better care , "according to the magazine
prescribe who does not hesitate to specify its target in its editorial:
"Without waiting for the decisions of the authorities, patients and
caregivers should choose to exclude care and prefer best proven
treatments. " A call for patients and doctors to take things in hand,
not always wait for the official decision. It must be said that the
procedures for suspension or prohibition by the health authorities are
often slow, especially when they require a European consensus. Protelos ,
one of the drugs contained in the blacklist Prescribing , the
illustrates perfectly.
For years Prescribing and other experts believe that the risk / benefit
ratio of this drug was indicated in the osteoporosis is severe adverse.
In 2011, the French Medicines Agency (MSNA) already asked European
revaluation, before settling down to note the drug and reduce its
reimbursement rates.
But it was not until January 10 that the reassessment finally enters the terminal phase, with a recommendation to suspend the European Pharmacovigilance Committee. However, it will take several weeks before it is effective. Subscribers doctors prescribe will probably not waited so long. The case study Probably as they have already banned their personal pharmacopoeia quinine (Hexaquinine, Okimus, Quinine vitamin C Grand) sometimes given to treat cramps when he is, reminds Prescribing , a drug that "exposed to serious adverse effects, sometimes fatal. " Again, the reaction of the French authorities seem timid . The Transparency Committee estimated in April 2011 that "given the low efficiency of benign conditions that resolve spontaneously and the risk of rare but severe allergic accident, these proprietary medical service is considered insufficient" . Conclusion: withdrawal? No, simple delisting. Even more inexplicable, the case of Motilium , whose medical service is only "moderate" for the "relief of symptoms of nausea and vomiting-type" and frankly "insufficient" in other directions, as assessed by the 'MSNA in 2007. Just check the package leaflet on the new Public Database drugs to see the potential cardiac toxicity mentioned in chapter
(4) of the very few possible side effects (affects less than one in 10,000 patients): " unexpected death resulting from sudden cessation of cardiac function in a person who may or may not have known heart disease. " Low activity potentially fatal withdrawal? No, European ongoing reassessment. Last example, among the 68 blacklisted Prescribing the Xolair , recent drug administered by injection every two weeks, which cost the improvement of medical service rendered "remains minor in the usual care of allergic asthmatic patients severe poorly controlled (balanced, Ed) by high-dose inhaled corticosteroids plus a beta2-agonist long-acting, "according to the opinion of the High Health Authority . Prescribing notes that "open to infection, anaphylaxis, serum disease, arterial thromboembolism, heart and brain. " Banned? No, he has just received the European level of an expansion of its indications ! It could soon be given against ... hives. When looking closer, yes it is good, sometimes not rely entirely on the work of health authorities.
But it was not until January 10 that the reassessment finally enters the terminal phase, with a recommendation to suspend the European Pharmacovigilance Committee. However, it will take several weeks before it is effective. Subscribers doctors prescribe will probably not waited so long. The case study Probably as they have already banned their personal pharmacopoeia quinine (Hexaquinine, Okimus, Quinine vitamin C Grand) sometimes given to treat cramps when he is, reminds Prescribing , a drug that "exposed to serious adverse effects, sometimes fatal. " Again, the reaction of the French authorities seem timid . The Transparency Committee estimated in April 2011 that "given the low efficiency of benign conditions that resolve spontaneously and the risk of rare but severe allergic accident, these proprietary medical service is considered insufficient" . Conclusion: withdrawal? No, simple delisting. Even more inexplicable, the case of Motilium , whose medical service is only "moderate" for the "relief of symptoms of nausea and vomiting-type" and frankly "insufficient" in other directions, as assessed by the 'MSNA in 2007. Just check the package leaflet on the new Public Database drugs to see the potential cardiac toxicity mentioned in chapter
(4) of the very few possible side effects (affects less than one in 10,000 patients): " unexpected death resulting from sudden cessation of cardiac function in a person who may or may not have known heart disease. " Low activity potentially fatal withdrawal? No, European ongoing reassessment. Last example, among the 68 blacklisted Prescribing the Xolair , recent drug administered by injection every two weeks, which cost the improvement of medical service rendered "remains minor in the usual care of allergic asthmatic patients severe poorly controlled (balanced, Ed) by high-dose inhaled corticosteroids plus a beta2-agonist long-acting, "according to the opinion of the High Health Authority . Prescribing notes that "open to infection, anaphylaxis, serum disease, arterial thromboembolism, heart and brain. " Banned? No, he has just received the European level of an expansion of its indications ! It could soon be given against ... hives. When looking closer, yes it is good, sometimes not rely entirely on the work of health authorities.
No comments:
Post a Comment